Physician

Peter I Yi, M.D.

According to 2025 Medicare claims, Peter Yi, M.D. (NPI: 1457499618) practices hematology/oncology in the Trenton-Princeton, NJ market, with the plurality of this provider's patient population coming from Mercer, NJ. This provider's primary affiliated billing organization is PRINCETON MEDICAL GROUP,P.A. (NPI: 1063513679; TIN: 222306123) and primary practice location at 08536-1913. Yi is affiliated with the Aledade 25 NJ MSSP Enhanced (ACO ID: A3891), participating under the MSSP model.

Yi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 298 traditional Medicare patients, billed 149,705 HCPCS/CPT codes, and received $2,040,798 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,781 prescription claims across 274 beneficiaries totaling $4,240,227 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 24 claims. Open Payments data shows 2 records totaling $49. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,402,866 to $4,240,227. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,578 to $1,581.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	450	367,413	$3,000,872
2016	455	336,940	$2,681,766
2017	428	311,346	$2,398,193
2018	419	311,907	$2,675,012
2019	397	181,304	$2,434,975
2020	352	187,281	$2,293,666
2021	385	257,844	$2,837,486
2022	376	224,268	$2,594,697
2023	332	186,819	$2,860,938
2024	298	149,705	$2,040,798

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	270	1,725	$1,402,866
2016	271	1,839	$1,130,137
2017	273	1,652	$913,079
2018	267	1,677	$990,198
2019	268	1,558	$1,111,801
2020	277	1,625	$1,463,439
2021	268	1,707	$2,282,214
2022	283	1,904	$3,032,924
2023	274	1,705	$2,948,777
2024	274	1,781	$4,240,227

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	115	$28,557
2016	N/R	33	$3,617
2017	N/R	12	$6,098
2018	N/R	N/R	N/R
2019	N/R	32	$4,726
2020	N/R	80	$6,938
2021	N/R	91	$4,907
2022	N/R	116	$18,063
2023	N/R	24	$4,727
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	241	1,000	$104
84443	Blood test, thyroid stimulating hormone (tsh)	238	985	$16
80053	Blood test, comprehensive group of blood chemicals	242	981	$10
36415	Insertion of needle into vein for collection of blood sample	253	1,115	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	253	1,090	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	102	2,849	$1,585,338
Xtandi	Enzalutamide	33	990	$458,837
Jakafi	Ruxolitinib Phosphate	14	420	$242,577
Tagrisso	Osimertinib Mesylate	12	360	$201,859
Lupron Depot	Leuprolide Acetate	30	1,144	$74,295

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$49	Janssen Pharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Peter I. Yi, M.D.?

Tedicare shows public-source Medicare data for Peter I. Yi, M.D. (NPI 1457499618), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Peter I. Yi, M.D. have ACO affiliation data?

Peter I. Yi, M.D. is shown with ACO affiliation data for Aledade 25 NJ MSSP Enhanced (MSSP, ACO ID A3891).

What billing organization is linked to Peter I. Yi, M.D.?

Peter I. Yi, M.D. is linked to PRINCETON MEDICAL GROUP,P.A. (billing NPI 1063513679) in the available physician profile data.

Does Peter I. Yi, M.D. have Open Payments data?

Peter I. Yi, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.